Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease.

Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease.

At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.

Lyterian Therapeutics

Ingrid Wertz

Veronica Kuiper

Julie Kim

Jonathan Baell

Tracy Yuen

The Leadership Team at Lyterian Therapeutics drives the strategic vision and operational execution of the company's mission to develop innovative medicines targeting disease resolution. Comprising seasoned experts in biology and research, including Principal Scientists and a Vice President, this team harmonizes scientific insights and business acumen to oversee research initiatives, guide product development, and ensure alignment with the company's commitment to leveraging homeostatic mechanisms for therapeutic advancements.

Leadership Team

About

Team members

Other teams at Lyterian Therapeutics

Research and Development